Targeting neurohumoral signaling to treat pulmonary hypertension: The right ventricle coming into focus

Circulation

Volumn 126, Issue 24, 2012, Pages 2806-2808

  Maron, Bradley A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Adrenergic; Beta; Editorials; Hypertension; Pulmonary; Receptors; Right ventricular dysfunction

Indexed keywords

BETA ADRENERGIC RECEPTOR; DOPAMINE RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2;

CARDIOVASCULAR PARAMETERS; CORONARY BLOOD FLOW RESERVE; EDITORIAL; HEART FAILURE; HEART PERFUSION; HEART RIGHT VENTRICLE; HUMAN; HYPERALDOSTERONISM; NEUROHUMORAL SIGNALING; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION;

ANIMALS; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, DOPAMINE D1; XANTHENES;

EID: 84870910696     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.149534     Document Type: Editorial

References (22)

1. Puwanant S, Park M, Popovic ZB, Tang WH, Farha S, George D, Sharp J, Puntawangkoon J, Loyd JE, Erzurum SC, Thomas JD. Ventricular geometry, strain, and rotational mechanics in pulmonary hypertension. Circulation. 2010;121:259-266.
2. Meyer P, Filippatos GS, Ahmed MI, Iskandrian AE, Bittner V, Perry GJ, White M, Aban IB, Mujib M, Dell'Italia LJ, Ahmed A. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation. 2010;121:252-258.
3. Kawut SM, Barr RG, Lima JA, Praestgaard A, Johnson WC, Chahal H, Ogunyankin KO, Bristow MR, Kizer JR, Tandri H, Bluemke DA. Right ventricular structure is associated with the risk of heart failure and cardiovascular death: the Multi-Ethnic Study of Atherosclerosis (MESA)-Right Ventricle Study. Circulation. 2012;126:1681-1688.
4. Zaffran S, Kelly RG, Meilhac SM, Buckingham ME, Brown NA. Right ventricular myocardium derives from the anterior heart field. Circ Res. 2004;95:261-268.
5. Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation. 2009;120:992-1007.
6. Gold FL, Bache RJ. Transmural right ventricular blood flow during acute pulmonary artery hypertension in the sedated dog. Evidence for subendocardial ischemia despite residual vasodilator reserve. Circ Res. 1982; 51:196-204.
7. Gaasch WH, Zile MR. Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol. 2011;58:1733-1740.
8. Shah SJ. Pulmonary hypertension. JAMA. 2012;308:1366-1374.
9. Rondelet B, Dewachter C, Kerbaul F, Kang X, Fesler P, Brimioulle S, Naeije R, Dewachter L. Prolonged overcirculation-induced pulmonary arterial hypertension as a cause of right ventricular failure. Eur Heart J. 2012;33:1017-1026.
10. Nagendran J, Gurtu V, Fu DZ, Dyck JR, Haromy A, Ross DB, Rebeyka IM, Michelakis ED. A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted. J Thorac Cardiovasc Surg. 2008;136:168-178, 178 e161-e163.
11. Nagendran J, Michelakis ED. Mitochondrial NOS is upregulated in the hypoxic heart: implications for the function of the hypertrophied right ventricle. Am J Physiol Heart Circ Physiol. 2009;296:H1723-H1726.
12. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116:238-248.
13. Fang YH, Piao L, Hong Z, Toth PT, Marsboom G, Bache-Wiig P, Rehman J, Archer SL. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. J Mol Med (Berl.) 2012;90: 31-43.
14. Hajjar RJ, MacRae CA. Adrenergic-receptor polymorphisms and heart failure. N Engl J Med. 2002;347:1196-1199.
15. de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, Francois C, Schalij I, Dorfmuller P, Simonneau G, Fadel E, Perros F, Boonstra A, Postmus PE, van der Velden J, Vonk-Noordegraaf A, Humbert M, Eddahibi S, Guignabert C. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186:780-789.
16. Maron BA, Opotowsky AR, Landzberg MJ, Loscalzo J, Waxman AB, Leopold JA. Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. Eur J Heart Fail. October 30, 2012. doi: 10.1093/eurjhf/hfs173. http://eurjhf.oxfordjournals.org. Accessed November 10, 2012.
17. Apitz C, Honjo O, Friedberg MK, Assad RS, Van Arsdell G, Humpl T, Redington AN. Beneficial effects of vasopressors on right ventricular function in experimental acute right ventricular failure in a rabbit model. Thorac Cardiovasc Surg. 2012;60:17-23.
18. So PP, Davies RA, Chandy G, Stewart D, Beanlands RS, Haddad H, Pugliese C, Mielniczuk LM. Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol. 2012;109:1504-1509.
19. Piao L, Fang Y-H, Parikh KS, Ryan JJ, D'Souza KM, Theccanat T, Toth PT, Pogoriler J, Paul J, Blaxall BC, Akhter SA, Arther SL. GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation. 2012;126:2859-2869.
20. Rengo G, Lymperopoulos A, Zincarelli C, Femminella G, Liccardo D, Pagano G, de Lucia C, Cannavo A, Gargiulo P, Ferrara N, Perrone Filardi P, Koch W, Leosco D. Blockade of beta-adrenoceptors restores the GRK2-mediated adrenal alpha(2)-adrenoceptor-catecholamine production axis in heart failure. Br J Pharmacol. 2012;166:2430-2440.
21. Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn GW 2nd, Koch WJ. Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem. 2012;285: 16378-16386.
22. Right Heart Failure Summit 2012, Boston, MA, October 12-13, 2012. Program. http://www.medfound.com/rhfs/index.html. Accessed on October 23, 2012.